格雷夫茲病市場：依治療方法、給藥途徑、分銷管道和地區分類

預計2024年全球格雷夫茲病市場規模為4.101億美元，預計2031年將達5.702億美元，2024年至2031年複合年成長率為4.8%。

圖 1. 2024 年格雷夫茲病市場佔有率(%)，依地區分類

格雷夫茲病，也稱為毒性瀰漫性甲狀腺腫，是一種導致甲狀腺激素分泌過多的自體免疫疾病。它是甲狀腺亢進最常見的原因。當免疫系統產生刺激甲狀腺生長並分泌過多甲狀腺激素的抗體時，就會發生格雷夫茲病。過量的甲狀腺激素會加速身體的許多功能。格雷夫茲病的常見症狀包括震顫、焦慮、體重減輕、心悸和對熱敏感。格雷夫茲病影響約 0.5% 的總人口，並且在女性中更為常見。這種疾病被認為具有遺傳因素，並且經常在家族中遺傳。儘管格雷夫茲病無法治愈，但可以透過抗甲狀腺藥物、放射性碘療法以及切除部分或全部甲狀腺的手術來有效治療。

市場動態：

全球格雷夫茲病市場的成長是由人口老化加劇和甲狀腺疾病盛行率上升等因素所推動的。據美國甲狀腺協會稱，格雷夫斯病每年影響約 0.5% 的美國人口。醫療保健支出的增加、新治療方案的出現以及對疾病診斷和管理的認知不斷提高也將推動市場成長。然而，與抗甲狀腺藥物相關的副作用，如體重增加、脫髮和肝損傷，可能會阻礙市場成長。此外，與手術和放射性碘治療相關的高成本也可能阻礙市場成長。新藥物分子和聯合治療的持續藥物創新和臨床試驗可能會在預測期內為市場成長提供利潤豐厚的機會。

本研究的主要特點

• 本報告對全球格雷夫茲病市場進行了詳細分析，並提出了以2023年為基準年的預測期（2024-2031年）的市場規模和年複合成長率（CAGR%）。
• 它闡明了不同細分市場的潛在商機，並解釋了該市場中有吸引力的投資提案的矩陣。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
• 根據公司亮點、產品系列、主要亮點、績效和策略等參數，了解全球格雷夫茲病市場的主要企業概況。
• 該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
• 全球格雷夫茲病市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
• 透過用於全球格雷夫茲病市場分析的各種策略矩陣，將促進相關人員的決策。

目錄

第1章 研究目的與前提

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行概述
• 一致的機會地圖 (COM)

第3章 市場動態、法規與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因素
  • 機會
• 影響分析
• 市場趨勢
• 監管場景
• 收購和合作場景
• 資金籌措和投資
• PEST分析
• 波特的分析

第4章全球格雷夫茲病市場－冠狀病毒（COVID-19）大流行的影響

• 整體影響
• 政府舉措
• COVID-19 對市場的影響

第5章全球格雷夫茲病市場，依治療方法，2019-2031 年，（百萬美元）

• 介紹
• 抗甲狀腺藥物
• BETA阻斷劑
• 碘療法
• 放射性碘治療
• 其他

第6章 全球格雷夫茲病市場，依給藥途徑，2019-2031 年（百萬美元）

• 介紹
• 口服
• 胃腸外的
• 其他

第 7 章 全球格雷夫茲病市場，依通路分類，2019-2031 年（百萬美元）

• 介紹
• 醫院藥房
• 零售藥房
• 網路藥房

第8章全球格雷夫茲病市場，按地區，2019-2031 年（百萬美元）

• 介紹
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東

第9章 競爭格局

• 公司簡介
  • AbbVie Inc.
  • Pfizer Inc.
  • RLC LABS, Inc.
  • Merck KGaA
  • Eisai Co., Ltd.
  • Novartis AG
  • Mylan NV
  • Aspen Pharmacare Holdings Limited
  • Sanofi
  • GlaxoSmithKline plc
  • AstraZeneca
  • Horizon Therapeutics plc
  • Alara Pharmaceutical Corporation
  • Antares Pharma, Inc.
  • Apitope Technology（Bristol）Ltd.
  • IONIS Pharmaceuticals, Inc.
  • Immunovant, Inc.
  • HanAll Biopharma Co., Ltd.
  • Cara Therapeutics

第10章分析師建議

• 升起和降落
• 綜合機會圖

第11章 參考文獻與調查方法

• 參考
• 調查方法

Global graves' disease (overactive thyroid) market is estimated to be valued at USD 410.1 Mn in 2024 and is expected to reach USD 570.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.8% from 2024 to 2031.

Figure 1. Graves' Disease (Overactive Thyroid) Market Share (%), By Region, 2024

Graves' disease, also known as toxic diffuse goiter, is an autoimmune disease that results in overproduction of thyroid hormones (hyperthyroidism). It is the most common cause of hyperthyroidism. Graves' disease develops when the immune system makes antibodies that stimulate the thyroid gland to grow and produce excess thyroid hormones. Excess thyroid hormones causes speeding up of many of the body's functions. Common symptoms of Graves' disease include tremors, anxiety, weight loss, heart palpitations, and heat intolerance. Graves' disease affects about 0.5% of the general population, although the disease is more common in women. The disease is believed to have a genetic component, and often runs in families. Although it is not curable, Graves' disease can be effectively treated by antithyroid medications, radioactive iodine therapy, or surgery to remove part or all of the thyroid gland.

Market Dynamics:

Global graves' disease (overactive thyroid) market growth is driven by factors like growing aging population and increasing prevalence of thyroid disorders. According to American Thyroid Association, Graves' disease affects about 0.5% of the population in the U.S. every year. Increasing healthcare expenditure, availability of newer treatment options, and rising awareness about disease diagnosis and management can also drive the market growth. However, side effects associated with antithyroid medications such as weight gain, hair loss and liver damage can hinder the market growth. High costs involved in surgeries and radioactive iodine therapy can also hamper the market growth. Ongoing drug innovations and clinical trials on newer drug molecules and combination therapies can offer lucrative opportunities for market growth over the forecast period.

Key Features of the Study:

• This report provides in-depth analysis of the global graves' disease (overactive thyroid) market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global graves' disease (overactive thyroid) market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AbbVie Inc., Pfizer Inc., RLC LABS, Inc., Merck KGaA, Eisai Co., Ltd., Novartis AG, Mylan N.V., Aspen Pharmacare Holdings Limited, Sanofi, GlaxoSmithKline plc, AstraZeneca, Horizon Therapeutics plc, Alara Pharmaceutical Corporation, Antares Pharma, Inc., Apitope Technology (Bristol) Ltd., IONIS Pharmaceuticals, Inc., Immunovant, Inc., HanAll Biopharma Co., Ltd., Cara Therapeutics
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global graves' disease (overactive thyroid) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global graves' disease (overactive thyroid) market

Detailed Segmentation-

• By Treatment
  • Anti-thyroid Drugs
  • Beta Blockers
  • Iodine Therapy
  • Radioactive Iodine Therapy
  • Others
• By Route of Administration
  • Oral
  • Parenteral
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AbbVie Inc.
  • Pfizer Inc.
  • RLC LABS, Inc.
  • Merck KGaA
  • Eisai Co., Ltd.
  • Novartis AG
  • Mylan N.V.
  • Aspen Pharmacare Holdings Limited
  • Sanofi
  • GlaxoSmithKline plc
  • AstraZeneca
  • Horizon Therapeutics plc
  • Alara Pharmaceutical Corporation
  • Antares Pharma, Inc.
  • Apitope Technology (Bristol) Ltd.
  • IONIS Pharmaceuticals, Inc.
  • Immunovant, Inc.
  • HanAll Biopharma Co., Ltd.
  • Cara Therapeutics

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Treatment
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Graves' Disease (Overactive Thyroid) Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Graves' Disease (Overactive Thyroid) Market, By Treatment, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Anti-thyroid Drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Beta Blockers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Iodine Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Radioactive Iodine Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Graves' Disease (Overactive Thyroid) Market, By Route of Administration, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Graves' Disease (Overactive Thyroid) Market, By Distribution Channel, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

8. Global Graves' Disease (Overactive Thyroid) Market, By Region, 2019 - 2031, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2019-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • RLC LABS, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck KGaA
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eisai Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Mylan N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Aspen Pharmacare Holdings Limited
  • Sanofi
  • GlaxoSmithKline plc
  • AstraZeneca
  • Horizon Therapeutics plc
  • Alara Pharmaceutical Corporation
  • Antares Pharma, Inc.
  • Apitope Technology (Bristol) Ltd.
  • IONIS Pharmaceuticals, Inc.
  • Immunovant, Inc.
  • HanAll Biopharma Co., Ltd.
  • Cara Therapeutics

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact